279 related articles for article (PubMed ID: 27189135)
1. Overcoming multidrug resistance in Dox-resistant neuroblastoma cell lines via treatment with HPMA copolymer conjugates containing anthracyclines and P-gp inhibitors.
Koziolová E; Janoušková O; Cuchalová L; Hvězdová Z; Hraběta J; Eckschlager T; Sivák L; Ulbrich K; Etrych T; Šubr V
J Control Release; 2016 Jul; 233():136-46. PubMed ID: 27189135
[TBL] [Abstract][Full Text] [Related]
2. Ability of polymer-bound P-glycoprotein inhibitor ritonavir to overcome multidrug resistance in various resistant neuroblastoma cell lines.
Koziolová E; Chytil P; Etrych T; Janoušková O
Anticancer Drugs; 2017 Nov; 28(10):1126-1130. PubMed ID: 28901962
[TBL] [Abstract][Full Text] [Related]
3. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
4. Reversion of P-gp-Mediated Drug Resistance in Ovarian Carcinoma Cells with PHPMA-Zosuquidar Conjugates.
Battistella C; Klok HA
Biomacromolecules; 2017 Jun; 18(6):1855-1865. PubMed ID: 28409628
[TBL] [Abstract][Full Text] [Related]
5. Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate.
Sivak L; Subr V; Tomala J; Rihova B; Strohalm J; Etrych T; Kovar M
Biomaterials; 2017 Jan; 115():65-80. PubMed ID: 27886555
[TBL] [Abstract][Full Text] [Related]
6. Synthesis of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of inhibitors of the ABC transporter that overcome multidrug resistance in doxorubicin-resistant P388 cells in vitro.
Subr V; Sivák L; Koziolová E; Braunová A; Pechar M; Strohalm J; Kabešová M; Ríhová B; Ulbrich K; Kovář M
Biomacromolecules; 2014 Aug; 15(8):3030-43. PubMed ID: 24978588
[TBL] [Abstract][Full Text] [Related]
7. Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance.
Braunová A; Kostka L; Sivák L; Cuchalová L; Hvězdová Z; Laga R; Filippov S; Černoch P; Pechar M; Janoušková O; Šírová M; Etrych T
J Control Release; 2017 Jan; 245():41-51. PubMed ID: 27871991
[TBL] [Abstract][Full Text] [Related]
8. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties.
Etrych T; Jelínková M; Ríhová B; Ulbrich K
J Control Release; 2001 May; 73(1):89-102. PubMed ID: 11337062
[TBL] [Abstract][Full Text] [Related]
9. Properties of HPMA copolymer-doxorubicin conjugates with pH-controlled activation: effect of polymer chain modification.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2006 Sep; 115(1):26-36. PubMed ID: 16899320
[TBL] [Abstract][Full Text] [Related]
10. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
[TBL] [Abstract][Full Text] [Related]
11. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
12. A thermally targeted elastin-like polypeptide-doxorubicin conjugate overcomes drug resistance.
Bidwell GL; Davis AN; Fokt I; Priebe W; Raucher D
Invest New Drugs; 2007 Aug; 25(4):313-26. PubMed ID: 17483874
[TBL] [Abstract][Full Text] [Related]
13. Nanotherapeutics with suitable properties for advanced anticancer therapy based on HPMA copolymer-bound ritonavir via pH-sensitive spacers.
Machová D; Koziolová E; Chytil P; Venclíková K; Etrych T; Janoušková O
Eur J Pharm Biopharm; 2018 Oct; 131():141-150. PubMed ID: 30075311
[TBL] [Abstract][Full Text] [Related]
14. HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity.
Ulbrich K; Etrych T; Chytil P; Jelínková M; Ríhová B
J Control Release; 2003 Feb; 87(1-3):33-47. PubMed ID: 12618021
[TBL] [Abstract][Full Text] [Related]
15. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
[TBL] [Abstract][Full Text] [Related]
16. Sequential therapy with redox-responsive glucolipid nanocarrier separately delivering siRNA and doxorubicin to overcome multidrug resistance.
Meng T; Lu B; Shao S; Yuan M; Liu X; Yuan H; Huang X; Hu F
Int J Pharm; 2017 Dec; 534(1-2):368-377. PubMed ID: 29051118
[TBL] [Abstract][Full Text] [Related]
17. HPMA-based polymer conjugates with drug combination.
Krakovicová H; Etrych T; Ulbrich K
Eur J Pharm Sci; 2009 Jun; 37(3-4):405-12. PubMed ID: 19491032
[TBL] [Abstract][Full Text] [Related]
18. Assessing the therapeutic efficacy of VEGFR-1-targeted polymer drug conjugates in mouse tumor models.
Shamay Y; Golan M; Tyomkin D; David A
J Control Release; 2016 May; 229():192-199. PubMed ID: 27001892
[TBL] [Abstract][Full Text] [Related]
19. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin release is not a prerequisite for the in vitro cytotoxicity of HPMA-based pharmaceuticals: in vitro effect of extra drug-free GlyPheLeuGly sequences.
Ríhová B; Strohalm J; Hovorka O; Subr V; Etrych T; Chytil P; Pola R; Plocová D; Boucek J; Ulbrich K
J Control Release; 2008 Apr; 127(2):110-20. PubMed ID: 18325618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
